1. Home
  2. CNF vs CVKD Comparison

CNF vs CVKD Comparison

Compare CNF & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNF
  • CVKD
  • Stock Information
  • Founded
  • CNF 1999
  • CVKD 2022
  • Country
  • CNF China
  • CVKD United States
  • Employees
  • CNF N/A
  • CVKD N/A
  • Industry
  • CNF Finance: Consumer Services
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • CNF Finance
  • CVKD Health Care
  • Exchange
  • CNF Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • CNF 35.7M
  • CVKD 29.5M
  • IPO Year
  • CNF 2018
  • CVKD 2023
  • Fundamental
  • Price
  • CNF $0.67
  • CVKD $11.15
  • Analyst Decision
  • CNF
  • CVKD Strong Buy
  • Analyst Count
  • CNF 0
  • CVKD 1
  • Target Price
  • CNF N/A
  • CVKD $32.00
  • AVG Volume (30 Days)
  • CNF 189.4K
  • CVKD 27.6K
  • Earning Date
  • CNF 08-27-2025
  • CVKD 08-19-2025
  • Dividend Yield
  • CNF N/A
  • CVKD N/A
  • EPS Growth
  • CNF N/A
  • CVKD N/A
  • EPS
  • CNF 0.08
  • CVKD N/A
  • Revenue
  • CNF $85,661,735.00
  • CVKD N/A
  • Revenue This Year
  • CNF $252.34
  • CVKD N/A
  • Revenue Next Year
  • CNF N/A
  • CVKD N/A
  • P/E Ratio
  • CNF $9.80
  • CVKD N/A
  • Revenue Growth
  • CNF N/A
  • CVKD N/A
  • 52 Week Low
  • CNF $0.37
  • CVKD $5.70
  • 52 Week High
  • CNF $2.84
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • CNF 44.28
  • CVKD 48.44
  • Support Level
  • CNF $0.68
  • CVKD $10.14
  • Resistance Level
  • CNF $0.88
  • CVKD $11.44
  • Average True Range (ATR)
  • CNF 0.08
  • CVKD 0.75
  • MACD
  • CNF -0.01
  • CVKD 0.07
  • Stochastic Oscillator
  • CNF 1.92
  • CVKD 74.38

About CNF CNFinance Holdings Limited each representing twenty (20)

CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: